Efficacy of onabotulinum toxin A injection in pediatric patients with non‐neurogenic detrusor overactivity

Bayrak, Ömer; Sadioglu, Erkan; Şen, Haluk; Dogan, Kazim; Erturhan, Sakıp; Şeçkiner, İlker

doi:10.1002/nau.23240

Cited by 11 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we see an unmet need to validate the efficacy and safety profile of this therapy analyzing our uropediatric collective. [6,7,11,12,24]. All of them demonstrated significant reduction of incontinence episodes and an increase of functional bladder capacity with minimal side effects.…”

Section: Discussionmentioning

confidence: 92%

“…In 2006 the first use of Botox in LUTC with mainly symptoms of overactive bladder in the pediatric population was reported as safe and effective [6]. Subsequently, few studies have been carried out investigating the use of Botox in the pediatric population for LUTC [1,[6][7][8][9][10][11][12]. In comparison to adult age studies, uropediatric studies on Botox in LUTC are more seldom and covered with smaller sample sizes.…”

Section: Discussionmentioning

confidence: 99%

“…However, the results of the discussed works are not perfectly comparable. While Bayrak and Blackburn describe only changes in individual symptoms, all other authors define a categorized response (full or partial response vs. failure) [6][7][8][9]11,24].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, in the pediatric age group the use of Botox has been reported to be equally safe and effective in children with overactive day-time LUTC [1,6]. However, only few trials investigated this topic [1,[6][7][8][9][10][11][12]. No randomized controlled trials have been conducted to date.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions: A Single Center Experience

Krafft¹,

Hirner²,

Hirner³

et al. 2021

J Urol Ren Dis

View full text Add to dashboard Cite

Introduction:To evaluate efficacy and safety of Botulinum Toxin A (Botox) injection in the detrusor for day-time lower urinary tract conditions with mainly overactive symptoms, we analyzed our uropediatric Botox-treated collective. Materials and Methods:21 Children who received a Botox treatment in our hospital between 2016 and 2020 for refractory day-time lower urinary tract conditions with mainly overactive symptoms with conclusive follow up were analyzed. In all cases we applicated 100 IU Botox.Results: Mean age of patients was 9,19 (±3,0). In 8/21 cases a preoperative urodynamic assessment was available. We reached a median follow up of 289 days (range 34-750). Mean bladder capacity increased from 157 ml (±18.4) to 213 ml (±24.5) (p = 0.001). Mean voiding frequency decreased from 7.4 (±0.61) to 6.2 (±0.55) (p = 0.015). 13/21 Patients (61.9%) encountered a partial or complete therapy response while 8/21 Children (38.1%) showed a therapy failure. Within the responder group, 8/13 Children (61, 5%) experienced an ongoing response. However, 5 Children relapsed on average in 176 days (±45, 5). 3 Children received a repeated injection of Botox. We observed no serious side effects.Discussion/Conclusion: Even though pediatric Botox therapy still lacks standardization; our study indicates a safe and effective use for day-time lower urinary tract conditions with mainly overactive symptoms in children who are resistant to common treatments. Moreover, we found a one-time injection in most cases to be sufficient to improve symptoms in the long term.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions: A Single Center Experience

Krafft¹,

Hirner²,

Hirner³

et al. 2021

J Urol Ren Dis

View full text Add to dashboard Cite

show abstract

“…But caution must be taken when BTX-A is used in patients under age 18 years of age. BTX is specified as pregnancy category C, where there are no adequate and well-controlled studies in children and it should only be used if the potential benefits justify the potential risk to the fetus [33,56,69,86,87].…”

Section: Side Effectsmentioning

confidence: 99%

The Current Role of Botox in a Pediatric Neurogenic Bladder Condition

Kroll

2019

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Purpose of Review The neurogenic bladder is a medical term that describes a variety of bladder and sphincter dysfunctions. There are two major dangerous functional problems in a child with neurogenic bladder: high intravesical pressure in the storage phase and high pressure during urination. Two basic goals for urologic treatment in those children are protection of urinary tract from complications and improvement of continence in older children. This review focuses on the current role of botulinum toxin treatment in children with neurogenic bladder. Recent Findings At the beginning, treatment in this group of children is conservative. Oral anticholinergic therapy is aimed at decreasing bladder pressures during the storage phase. Clean intermittent catheterization enables bladder emptying if voiding is insufficient. Nevertheless, in a number of children such an approach fails, in some patients, troublesome side effects occur. In cases when standard therapy provides no improvement or if complications develop on the proper conservative treatment, surgical procedures are suggested. Operations are aimed at the surgical enlargement of bladder capacity. There are some reports on the efficacy of cystoscopic detrusor botulinum toxin injections in the treatment of neurogenic bladder in children. Summary Cystoscopic administration of botulinum toxin represents an alternative method of treatment to surgery for children with neurogenic bladder and could be considered an alternative to oral anticholinergic therapy.

show abstract

Botulinum Toxin Treatment in Urological Disorders

Smith

Chancellor

2020

Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine

View full text Add to dashboard Cite

Efficacy of onabotulinum toxin A injection in pediatric patients with non‐neurogenic detrusor overactivity

Abstract: OnaBoNT-A injections can be used in the pediatric patients with NNDO as an effective and reliable procedure by decreasing voiding frequency, incontinence episodes, and increasing bladder capacity, with negligible side effects and complications.

Cited by 11 publications

References 14 publications

Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions: A Single Center Experience

Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions: A Single Center Experience

The Current Role of Botox in a Pediatric Neurogenic Bladder Condition

Botulinum Toxin Treatment in Urological Disorders

Contact Info

Product

Resources

About